NEW YORK (GenomeWeb News) – Companion diagnostics firm Oxford Cancer Biomarkers on Monday announced a biomarker discovery deal with AstraZeneca directed at an undisclosed drug.
Under the terms of the deal, OCB seeks to discover biomarkers that can predict responders and non-responders to the drug. OCB may also validate and further develop biomarkers resulting from the collaboration. AstraZeneca has the option to license the biomarkers.
Financial and other terms were not disclosed.